NCT00996346 arm group e8b0cd92ff01d23558db9ef0139b35fe [clinicaltrials_resource:NCT00996346/arm-group/e8b0cd92ff01d23558db9ef0139b35fe]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00996346 arm group e8b0cd92ff01d23558db9ef0139b35fe [clinicaltrials_resource:NCT00996346/arm-group/e8b0cd92ff01d23558db9ef0139b35fe]
Bio2RDF identifier
NCT00996346/arm-group/e8b0cd92ff01d23558db9ef0139b35fe
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... b0cd92ff01d23558db9ef0139b35fe
description [clinicaltrials_vocabulary:description]
Irinotecan at 80 mg/m2 weekly x3; Level 2: Temsirloimus 20 mg weekly x3
identifier
clinicaltrials_resource:NCT00996346/arm-group/e8b0cd92ff01d23558db9ef0139b35fe
title
NCT00996346 arm group e8b0cd92ff01d23558db9ef0139b35fe
@en
type
label
NCT00996346 arm group e8b0cd92 ...... 0cd92ff01d23558db9ef0139b35fe]
@en